Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate

Paolo Martelletti; Enrico Bentivegna; Michelangelo Luciani; Valerio Spuntarelli

doi:10.1007/s42399-020-00657-7

Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate

SN Compr Clin Med. 2020;2(12):2509-2510. doi: 10.1007/s42399-020-00657-7. Epub 2020 Nov 26.

Authors

Paolo Martelletti^{1

2}, Enrico Bentivegna², Michelangelo Luciani², Valerio Spuntarelli²

Affiliations

¹ Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
² Emergency Medicine & COVID-19 Unit, Sant'Andrea University Hospital, Rome, Italy.

Abstract

Headache occurs in only about 13% of patients within the cohort of presenting COVID-19 symptoms. The hypothesis that such a painful symptomatic picture could be considered a prognostic factor for COVID-19 positive evolution or its trend of severity, or the co-generation of hyposmia/anosmia and/or hypogeusia/ageusia, needs robust epidemiological data, punctual pathophysiological demonstrations, and a detailed comparative analysis on drug-drug interactions (DDIs).

Keywords: COVID-19; Cytokine release syndrome (CRS); Drug–drug interactions (DDIs); Emergency medicine; Headache; Prognostic factors.